{"id":672379,"date":"2022-03-23T12:08:00","date_gmt":"2022-03-23T12:08:00","guid":{"rendered":"https:\/\/www.capgemini.com\/fr-fr\/?post_type=research-and-insight&#038;p=672379"},"modified":"2025-03-04T04:30:07","modified_gmt":"2025-03-04T03:30:07","slug":"nouveau-modele-de-rd-pour-lindustrie-pharmaceutique","status":"publish","type":"research-and-insight","link":"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/","title":{"rendered":"Vers un nouveau mod\u00e8le de R&amp;D pour l\u2019industrie pharmaceutique"},"content":{"rendered":"\n<header class=\"wp-block-cg-blocks-hero-reusable header heroReusable  \"><div class=\"header-bgs\"><picture><source srcset=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/03\/2022-FR-Banner-PoV-Pharma-R-D.jpg?w=2880&amp;quality=70 1x, https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/03\/2022-FR-Banner-PoV-Pharma-R-D.jpg?w=2880&amp;quality=70 2x\" media=\"(min-width: 1500px)\"\/><source srcset=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/03\/2022-FR-Banner-PoV-Pharma-R-D.jpg?w=1440&amp;quality=70 1x, https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/03\/2022-FR-Banner-PoV-Pharma-R-D.jpg?w=2880&amp;quality=70 2x\" media=\"(min-width: 992px)\"\/><source srcset=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/03\/2022-FR-Banner-PoV-Pharma-R-D.jpg?w=1024&amp;quality=70 1x, https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/03\/2022-FR-Banner-PoV-Pharma-R-D.jpg?w=1024&amp;quality=70 2x\" media=\"(min-width: 768px)\"\/><source srcset=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/03\/2022-FR-Banner-PoV-Pharma-R-D.jpg?w=768&amp;quality=70 1x, https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/03\/2022-FR-Banner-PoV-Pharma-R-D.jpg?w=768&amp;quality=70 2x\" media=\"(min-width: 0)\"\/><img decoding=\"async\" src=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/03\/2022-FR-Banner-PoV-Pharma-R-D.jpg\" class=\"header-img header-img-d\" alt=\"\" style=\"object-fit:cover;object-position:52% 62%\" loading=\"eager\"\/><\/picture><\/div><div class=\"heroPictureCardHeaderShape\"><\/div><div class=\"container\"><div class=\"row\"><div class=\"col-md-12\"><div class=\"box\"><div class=\"boxTagWrapper\"><div class=\"tagInfo\"><div><span class=\"box-tag\">Life Sciences<\/span><\/div><\/div><div class=\"brandInfo\"><div class=\"brandLogo\"><img decoding=\"async\" loading=\"lazy\" src=\"\/wp-content\/themes\/capgemini2020\/assets\/images\/capgemini-invent.svg\" alt=\"capgemini-invent\"\/><\/div><\/div><\/div><div class=\"box-title\"><h1 data-maxlength=\"34\">Vers un nouveau mod\u00e8le de R&amp;D pour l\u2019industrie pharmaceutique<\/h1><\/div><div class=\"inner-row-insight download-btn\"><div class=\"col-md-4 downloadFiles addPadding\"><a class=\"button-download--small\" type=\"download\" href=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/06\/2022-FR-PoV-Pharma-R-D.pdf\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"Ouvrir dans une nouvelle fen\u00eatre\"><span>Point de Vue<\/span><span class=\"type\">2 MB  pdf<\/span><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/header>\n\n\n\n<section class=\"wp-block-cg-blocks-intro-para undefined section section--intro\"><div class=\"intro-para\"><div class=\"container\"><div class=\"row\"><div class=\"col-12 col-md-1\"><nav class=\"article-social\"><ul class=\"social-nav\"><li class=\"ip-order-fb\"><a href=\"https:\/\/www.facebook.com\/sharer\/sharer.php?u=https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"Ouvrir dans une nouvelle fen\u00eatre\"><i aria-hidden=\"true\" class=\"icon-fb\"><\/i><span class=\"sr-only\">Facebook<\/span><\/a><\/li><li class=\"ip-order-li\"><a href=\"https:\/\/www.linkedin.com\/sharing\/share-offsite\/?url=https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"Ouvrir dans une nouvelle fen\u00eatre\"><i aria-hidden=\"true\" class=\"icon-li\"><\/i><span class=\"sr-only\">Linkedin<\/span><\/a><\/li><\/ul><\/nav><\/div><div class=\"col-12 col-md-11 col-lg-10\"><h2 class=\"intro-para-title\">La course \u00e0 la cr\u00e9ation d\u2019un vaccin pour lutter contre le COVID-19 a expos\u00e9 le monde \u00e0 une r\u00e9alit\u00e9 que la communaut\u00e9 scientifique et pharmaceutique savait depuis d\u00e9j\u00e0 longtemps. <\/h2><p class=\"intro-para-content\">La biotechnologie permet d\u00e9sormais la synth\u00e8se de mol\u00e9cules biologiques dans les micro-organismes et autres cellules vivants utilisant la technologie de l\u2019ADN recombinant.<\/p><\/div><\/div><\/div><\/div><\/section>\n\n\n\n<section class=\"wp-block-cg-blocks-group undefined section section--article-content\"><div class=\"article-main-content\"><div class=\"container\"><div class=\"row\"><div class=\"col-12 col-md-11 col-lg-10 offset-md-1 offset-lg-1\"><div class=\"article-text article-quote-text\">\n<figure class=\"wp-block-image alignleft\"><img decoding=\"async\" src=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/2\/2022\/03\/POV-pharmaceutical-.png?w=211\" alt=\"\" class=\"wp-image-247274\"\/><\/figure>\n\n\n\n<p>L\u2019utilisation de ces th\u00e9rapies innovantes cr\u00e9e de nouvelles options pour traiter une multitude de maladies rares :&nbsp;maladies, cancer, Alzheimer,&nbsp;Huntington, et immunod\u00e9ficience.&nbsp;Cela explique que 7 des 10 m\u00e9dicaments les plus vendus sont biologiques.&nbsp;L\u2019ensemble des th\u00e9rapies mol\u00e9culaires repr\u00e9sentent au total&nbsp;75%&nbsp;de tous les nouveaux m\u00e9dicaments approuv\u00e9s aux \u00c9tats-Unis en 2020 et vont constituer une part croissante des ordonnances.&nbsp;La capacit\u00e9 \u00e0 concevoir ces petites mol\u00e9cules peut ouvrir de nouvelles voies pour cibler des maladies auparavant consid\u00e9r\u00e9s sans traitement m\u00e9dicamenteux possible.<\/p>\n\n\n\n<p>Le futur est tr\u00e8s int\u00e9ressant pour la sant\u00e9 de l\u2019humanit\u00e9.&nbsp;Mais il reste un enjeu.&nbsp;Si le secteur pharmaceutique ne r\u00e9invente pas son mod\u00e8le de R&amp;D, beaucoup de ces traitements prometteurs&nbsp;pourraient&nbsp;ne jamais \u00eatre distribu\u00e9s\u2026<\/p>\n\n\n\n<p>D\u00e9couvrez en plus dans le Point de Vue r\u00e9dig\u00e9 par les experts de <strong>Capgemini Invent<\/strong>.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/06\/2022-FR-PoV-Pharma-R-D.pdf\">T\u00e9l\u00e9chargez le Point de Vue<\/a><\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/section>\n\n\n\n<section class=\"wp-block-cg-blocks-profile-card undefined profile-card section profile-card-slider\"><div class=\"container profileCardContainer\"><div class=\"profile-box\"><div class=\"row\"><div class=\"col-md-6 col-lg-3\"><div class=\"box\"><div class=\"box-author-img\"><img decoding=\"async\" src=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/06\/Broderick-Jones.jpg?w=500&amp;quality=70\" srcset=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/06\/Broderick-Jones.jpg?w=500&amp;quality=70 1x, https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/06\/Broderick-Jones.jpg?w=1000&amp;quality=70 2x\" class=\"box-img\" alt=\"\" style=\"object-fit:cover;object-position:50% 50%\" loading=\"lazy\"\/><\/div><\/div><\/div><div class=\"col-md-6 col-lg-9 right-side-box\"><div class=\"row right-box\"><div class=\"col-lg-4 profile\"><h3 class=\"profile-title\">Broderick Jones<\/h3><p class=\"box-position\">Global Head of Life Science<br>Capgemini Invent<\/p><ul class=\"social-nav social-nav-icons\"><li><a aria-label=\"LinkedIn (en anglais seulement)\" href=\"https:\/\/www.linkedin.com\/in\/broderick-jones\" target=\"_blank\" rel=\"noopener noreferrer\"><i class=\"icon-li\" aria-hidden=\"true\"><\/i><\/a><\/li><\/ul><\/div><\/div><\/div><\/div><\/div><\/div><\/section>\n\n\n\n<section class=\"wp-block-cg-blocks-profile-card undefined profile-card section profile-card-slider\"><div class=\"container profileCardContainer\"><div class=\"profile-box\"><div class=\"row\"><div class=\"col-md-6 col-lg-3\"><div class=\"box\"><div class=\"box-author-img\"><img decoding=\"async\" src=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/06\/Connie-Wu.png?w=500&amp;quality=70\" srcset=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/06\/Connie-Wu.png?w=500&amp;quality=70 1x, https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/06\/Connie-Wu.png?w=1000&amp;quality=70 2x\" class=\"box-img\" alt=\"\" style=\"object-fit:cover;object-position:50% 50%\" loading=\"lazy\"\/><\/div><\/div><\/div><div class=\"col-md-6 col-lg-9 right-side-box\"><div class=\"row right-box\"><div class=\"col-lg-4 profile\"><h3 class=\"profile-title\">Connie Wu<\/h3><p class=\"box-position\">Customer First Consultant<br>Capgemini Invent<\/p><ul class=\"social-nav social-nav-icons\"><li><a aria-label=\"LinkedIn (en anglais seulement)\" href=\"https:\/\/www.linkedin.com\/in\/clwu\" target=\"_blank\" rel=\"noopener noreferrer\"><i class=\"icon-li\" aria-hidden=\"true\"><\/i><\/a><\/li><\/ul><\/div><\/div><\/div><\/div><\/div><\/div><\/section>\n","protected":false},"excerpt":{"rendered":"<p>La course \u00e0 la cr\u00e9ation d\u2019un vaccin pour lutter contre le COVID-19 a expos\u00e9 le monde \u00e0 une r\u00e9alit\u00e9 que la communaut\u00e9 scientifique et pharmaceutique savait depuis d\u00e9j\u00e0 longtemps : la biotechnologie permet d\u00e9sormais la synth\u00e8se de mol\u00e9cules biologiques dans les micro-organismes et autres cellules vivants utilisant la technologie de l\u2019ADN recombinant.<\/p>\n","protected":false},"author":157,"featured_media":674018,"template":"","meta":{"cg_dt_proposed_to":[21],"cg_seo_hreflang_relations":"[]","cg_seo_canonical_relation":"{\"uuid\":\"1a9f70f8-daa6-40d6-ad06-0a6a327005a8\",\"blogId\":\"\",\"domain\":\"\",\"sitePath\":\"\",\"postLink\":\"\",\"postId\":null,\"isSaved\":true,\"isCrossLink\":false,\"hasCrossLink\":false}","cg_seo_hreflang_x_default_relation":"{\"uuid\":\"8a60b0ce-ea7a-49c1-a2f7-6af54a1e98d9\",\"blogId\":\"\",\"domain\":\"\",\"sitePath\":\"\",\"postLink\":\"\",\"postId\":null,\"isSaved\":true,\"isCrossLink\":false,\"hasCrossLink\":false}","cg_dt_approved_content":true,"cg_dt_mandatory_content":false,"cg_dt_notes":"","cg_dg_source_changed":false,"cg_dt_link_disabled":true,"footnotes":"","related_resource_url":"","related_resource_id":0,"related_resource_size":"","related_resource_type":"","cg_author":0,"_yoast_wpseo_primary_theme":0,"primary_term":"","featured_focal_points":""},"tags":[172,173],"research-and-insight-type":[85],"theme":[],"brand":[31],"service":[],"industry":[73],"partners":[],"content-group":[],"class_list":["post-672379","research-and-insight","type-research-and-insight","status-publish","has-post-thumbnail","hentry","tag-life-sciences","tag-sante","research-and-insight-type-points-de-vue","brand-capgemini-invent","industry-life-sciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.8 (Yoast SEO v22.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Vers un nouveau mod\u00e8le de R&amp;D pour l\u2019industrie pharmaceutique - Capgemini France<\/title>\n<meta name=\"description\" content=\"La biotechnologie permet la synth\u00e8se de mol\u00e9cules biologiques dans les micro-organismes utilisant l&#039;ADN recombinant.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vers un nouveau mod\u00e8le de R&amp;D pour l\u2019industrie pharmaceutique\" \/>\n<meta property=\"og:description\" content=\"La biotechnologie permet la synth\u00e8se de mol\u00e9cules biologiques dans les micro-organismes utilisant l&#039;ADN recombinant.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/\" \/>\n<meta property=\"og:site_name\" content=\"Capgemini France\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-04T03:30:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/06\/2022-FR-WP-PoV-Pharma-R-D.png\" \/>\n\t<meta property=\"og:image:width\" content=\"720\" \/>\n\t<meta property=\"og:image:height\" content=\"377\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/\",\"url\":\"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/\",\"name\":\"Vers un nouveau mod\u00e8le de R&amp;D pour l\u2019industrie pharmaceutique - Capgemini France\",\"isPartOf\":{\"@id\":\"https:\/\/www.capgemini.com\/fr-fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/03\/2022-FR-Featured-Image-PoV-Pharma-R-D.jpg\",\"datePublished\":\"2022-03-23T12:08:00+00:00\",\"dateModified\":\"2025-03-04T03:30:07+00:00\",\"description\":\"La biotechnologie permet la synth\u00e8se de mol\u00e9cules biologiques dans les micro-organismes utilisant l'ADN recombinant.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/#primaryimage\",\"url\":\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/03\/2022-FR-Featured-Image-PoV-Pharma-R-D.jpg\",\"contentUrl\":\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/03\/2022-FR-Featured-Image-PoV-Pharma-R-D.jpg\",\"width\":454,\"height\":641},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Research &amp; insights\",\"item\":\"https:\/\/www.capgemini.com\/fr-fr\/research-and-insight\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vers un nouveau mod\u00e8le de R&amp;D pour l\u2019industrie pharmaceutique\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.capgemini.com\/fr-fr\/#website\",\"url\":\"https:\/\/www.capgemini.com\/fr-fr\/\",\"name\":\"Capgemini France\",\"description\":\"Just another www.capgemini.com site\",\"publisher\":{\"@id\":\"https:\/\/www.capgemini.com\/fr-fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.capgemini.com\/fr-fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.capgemini.com\/fr-fr\/#organization\",\"name\":\"Capgemini France\",\"url\":\"https:\/\/www.capgemini.com\/fr-fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.capgemini.com\/fr-fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/08\/Logo-Capgemini.png\",\"contentUrl\":\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/08\/Logo-Capgemini.png\",\"width\":202,\"height\":60,\"caption\":\"Capgemini France\"},\"image\":{\"@id\":\"https:\/\/www.capgemini.com\/fr-fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Vers un nouveau mod\u00e8le de R&amp;D pour l\u2019industrie pharmaceutique - Capgemini France","description":"La biotechnologie permet la synth\u00e8se de mol\u00e9cules biologiques dans les micro-organismes utilisant l'ADN recombinant.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/","og_locale":"fr_FR","og_type":"article","og_title":"Vers un nouveau mod\u00e8le de R&amp;D pour l\u2019industrie pharmaceutique","og_description":"La biotechnologie permet la synth\u00e8se de mol\u00e9cules biologiques dans les micro-organismes utilisant l'ADN recombinant.","og_url":"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/","og_site_name":"Capgemini France","article_modified_time":"2025-03-04T03:30:07+00:00","og_image":[{"width":720,"height":377,"url":"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/06\/2022-FR-WP-PoV-Pharma-R-D.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/","url":"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/","name":"Vers un nouveau mod\u00e8le de R&amp;D pour l\u2019industrie pharmaceutique - Capgemini France","isPartOf":{"@id":"https:\/\/www.capgemini.com\/fr-fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/#primaryimage"},"image":{"@id":"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/#primaryimage"},"thumbnailUrl":"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/03\/2022-FR-Featured-Image-PoV-Pharma-R-D.jpg","datePublished":"2022-03-23T12:08:00+00:00","dateModified":"2025-03-04T03:30:07+00:00","description":"La biotechnologie permet la synth\u00e8se de mol\u00e9cules biologiques dans les micro-organismes utilisant l'ADN recombinant.","breadcrumb":{"@id":"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/#primaryimage","url":"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/03\/2022-FR-Featured-Image-PoV-Pharma-R-D.jpg","contentUrl":"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/03\/2022-FR-Featured-Image-PoV-Pharma-R-D.jpg","width":454,"height":641},{"@type":"BreadcrumbList","@id":"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Research &amp; insights","item":"https:\/\/www.capgemini.com\/fr-fr\/research-and-insight\/"},{"@type":"ListItem","position":2,"name":"Vers un nouveau mod\u00e8le de R&amp;D pour l\u2019industrie pharmaceutique"}]},{"@type":"WebSite","@id":"https:\/\/www.capgemini.com\/fr-fr\/#website","url":"https:\/\/www.capgemini.com\/fr-fr\/","name":"Capgemini France","description":"Just another www.capgemini.com site","publisher":{"@id":"https:\/\/www.capgemini.com\/fr-fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.capgemini.com\/fr-fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.capgemini.com\/fr-fr\/#organization","name":"Capgemini France","url":"https:\/\/www.capgemini.com\/fr-fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.capgemini.com\/fr-fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/08\/Logo-Capgemini.png","contentUrl":"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/08\/Logo-Capgemini.png","width":202,"height":60,"caption":"Capgemini France"},"image":{"@id":"https:\/\/www.capgemini.com\/fr-fr\/#\/schema\/logo\/image\/"}}]}},"theme_term_info":[],"industry_term_info":[{"id":73,"name":"Life Sciences"}],"services_term_info":[],"partners_term_info":[],"brand_term_info":[{"id":31,"name":"Capgemini Invent","slug":"capgemini-invent"}],"brand_term":[{"id":31,"slug":"capgemini-invent"}],"parsely":{"version":"1.1.0","canonical_url":"https:\/\/capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/","smart_links":{"inbound":0,"outbound":0},"traffic_boost_suggestions_count":0,"meta":{"@context":"https:\/\/schema.org","@type":"NewsArticle","headline":"Vers un nouveau mod\u00e8le de R&amp;D pour l\u2019industrie pharmaceutique","url":"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/","mainEntityOfPage":{"@type":"WebPage","@id":"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/"},"thumbnailUrl":"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/03\/2022-FR-Featured-Image-PoV-Pharma-R-D.jpg?w=150&h=150&crop=1","image":{"@type":"ImageObject","url":"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/03\/2022-FR-Featured-Image-PoV-Pharma-R-D.jpg"},"articleSection":"Uncategorized","author":[],"creator":[],"publisher":{"@type":"Organization","name":"Capgemini France","logo":""},"keywords":["life sciences","sant\u00e9"],"dateCreated":"2022-03-23T12:08:00Z","datePublished":"2022-03-23T12:08:00Z","dateModified":"2025-03-04T03:30:07Z"},"rendered":"<meta name=\"parsely-title\" content=\"Vers un nouveau mod\u00e8le de R&amp;D pour l\u2019industrie pharmaceutique\" \/>\n<meta name=\"parsely-link\" content=\"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/nouveau-modele-r-et-d-industrie-pharmaceutique\/\" \/>\n<meta name=\"parsely-type\" content=\"post\" \/>\n<meta name=\"parsely-image-url\" content=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/03\/2022-FR-Featured-Image-PoV-Pharma-R-D.jpg?w=150&amp;h=150&amp;crop=1\" \/>\n<meta name=\"parsely-pub-date\" content=\"2022-03-23T12:08:00Z\" \/>\n<meta name=\"parsely-section\" content=\"Uncategorized\" \/>\n<meta name=\"parsely-tags\" content=\"life sciences,sant\u00e9\" \/>","tracker_url":"https:\/\/cdn.parsely.com\/keys\/capgemini.com\/p.js"},"archive_status":false,"featured_image_src":"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/03\/2022-FR-Featured-Image-PoV-Pharma-R-D.jpg","featured_image_alt":"","jetpack_sharing_enabled":true,"distributor_meta":false,"distributor_terms":false,"distributor_media":false,"distributor_original_site_name":"Capgemini France","distributor_original_site_url":"https:\/\/www.capgemini.com\/fr-fr","push-errors":false,"tag_names":["Life Sciences","Sant\u00e9"],"featured_image_url":"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/03\/2022-FR-Featured-Image-PoV-Pharma-R-D.jpg","_links":{"self":[{"href":"https:\/\/www.capgemini.com\/fr-fr\/wp-json\/wp\/v2\/research-and-insight\/672379","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.capgemini.com\/fr-fr\/wp-json\/wp\/v2\/research-and-insight"}],"about":[{"href":"https:\/\/www.capgemini.com\/fr-fr\/wp-json\/wp\/v2\/types\/research-and-insight"}],"author":[{"embeddable":true,"href":"https:\/\/www.capgemini.com\/fr-fr\/wp-json\/wp\/v2\/users\/157"}],"version-history":[{"count":20,"href":"https:\/\/www.capgemini.com\/fr-fr\/wp-json\/wp\/v2\/research-and-insight\/672379\/revisions"}],"predecessor-version":[{"id":776253,"href":"https:\/\/www.capgemini.com\/fr-fr\/wp-json\/wp\/v2\/research-and-insight\/672379\/revisions\/776253"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.capgemini.com\/fr-fr\/wp-json\/wp\/v2\/media\/674018"}],"wp:attachment":[{"href":"https:\/\/www.capgemini.com\/fr-fr\/wp-json\/wp\/v2\/media?parent=672379"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.capgemini.com\/fr-fr\/wp-json\/wp\/v2\/tags?post=672379"},{"taxonomy":"research-and-insight-type","embeddable":true,"href":"https:\/\/www.capgemini.com\/fr-fr\/wp-json\/wp\/v2\/research-and-insight-type?post=672379"},{"taxonomy":"theme","embeddable":true,"href":"https:\/\/www.capgemini.com\/fr-fr\/wp-json\/wp\/v2\/theme?post=672379"},{"taxonomy":"brand","embeddable":true,"href":"https:\/\/www.capgemini.com\/fr-fr\/wp-json\/wp\/v2\/brand?post=672379"},{"taxonomy":"service","embeddable":true,"href":"https:\/\/www.capgemini.com\/fr-fr\/wp-json\/wp\/v2\/service?post=672379"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.capgemini.com\/fr-fr\/wp-json\/wp\/v2\/industry?post=672379"},{"taxonomy":"partners","embeddable":true,"href":"https:\/\/www.capgemini.com\/fr-fr\/wp-json\/wp\/v2\/partners?post=672379"},{"taxonomy":"content-group","embeddable":true,"href":"https:\/\/www.capgemini.com\/fr-fr\/wp-json\/wp\/v2\/content-group?post=672379"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}